Metroprolol Succinate,Precautions,Supplements,Interaction,Veterinary Vaccines, Safety,Formulations,Generic Distributor,Informatiom on Diseases,API Service Provider,Drug,Exporters,Treatment,Causes,Medical,Dosages,Health Conditions,Exporters,Generic,Drug Reaction,Prevention,Active Pharmaceutical Ingredients,Distributors,care,allergy,Drug Suppliers Worldwide,veterinary vaccines,Diseases,Vitamins,Export,Adverse Drug Reaction,Antidiabetic,Prevention,Pharmaceutical Development & Technology,Drug Manufacturer,Emergency,Importer,Taj Pharmaceuticals Ltd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Metroprolol-succinate

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Metroprolol succinate Manufacturers in India Suppliers Metroprolol succinate Exporters Distributors Metroprolol succinate api active pharmaceuticals ingredients Metroprolol succinate manufacturers Side Effects bulk drugs raw material Metroprolol succinate companies Side Effects Importers Metroprolol succinate Metroprolol succinate Exporters Metroprolol succinate exporters FDA Metroprolol succinate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Metroprolol succinate manufacturing pharmaceutical drugs pharmaceutical intermediates Metroprolol succinate pharmaceutical chemicals pharmaceutical raw materials Metroprolol succinate active pharmaceutical ingredients Metroprolol succinate committee active pharmaceutical ingredients manufacturer Metroprolol succinate Active Pharmaceutical Ingredients manufacturer Metroprolol succinate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Metroprolol succinate, Metroprolol succinate manufacturer India, Metroprolol succinate product, Metroprolol succinate products, Api preparation, Certificate of Analysis API manufacturer product, Metroprolol succinate anti ulcer product, Certificate of Origin COA Metroprolol succinate COS Metroprolol succinate, pharmaceutical generic, pharmaceutical drug, medical, Metroprolol succinate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Metroprolol succinate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Metroprolol succinate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Metroprolol succinate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Metroprolol succinate ingredients, api, HIV Metroprolol succinate, tablets, capsules, syrup & protein Metroprolol succinate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Metroprolol succinate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Metroprolol succinate WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

long-term treatment of chest pain

HOME >> Pharmaceuticals API List 2 >> Metroprolol Succinate >> Precautions

PRECAUTIONS
Metroprolol succinate CAS NO 98418-47-4

Metoprolol Succinate extended-release tablets should be used with caution in patients with impaired hepatic function. In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.

Worsening cardiac failure may occur during up-titration of Metoprolol Succinate extended-release tablets. If such symptoms occur, diuretics should be increased and the dose of Metoprolol Succinate extended-release tablets should not be advanced until clinical stability is restored. It may be necessary to lower the dose of Metoprolol Succinate extended-release tablets or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of Metoprolol Succinate extended-release tablets.

Patients should be advised to take Metoprolol Succinate extended-release tablets regularly and continuously, as directed, preferably with or immediately following meals. If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). Patients should not interrupt or discontinue Metoprolol Succinate extended-release tablets without consulting the physician.

Patients should be advised
(1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with Metoprolol Succinate extended-release tablets has been determined;
(2) to contact the physician if any difficulty in breathing occurs;
(3) to inform the physician or dentist before any type of surgery that he or she is taking Metoprolol Succinate extended-release tablets.

Heart failure patients should be advised to consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS >>

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

More Api at Taj Pharmaceuticals Ltd.

Lacidipine	Lamotrigine	Lansoprazole	Levetiracetam	Levo Cetirizine	Levofloxacin	Loratadine	Losartan Potassium	Metoprolol Succinate	Montelukast Sodium	Moxifloxacin HCl
Naproxen	Naratriptan	Norfloxacin	Nizatidine	Olmesartan	Omeprazole	Omeprazole Sodium	Oxaprozin	Paroxetine	Pantoprazole	Primidone

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.